NCT01623518已完成1 期
A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- Safety
研究概览
简要总结
This is a first in man dose escalation study, to assess the safety and immunogenicity of the candidate influenza vaccine ChAdOx1-NP+M1. All volunteers recruited will be healthy adults aged 18-50. Volunteers will be enrolled and doses will be escalated according to a "3+3" study plan. Up to 24 volunteers will be vaccinated. Following one dose of the vaccine, volunteers will be followed up to assess the side effect profile of the vaccine and to take blood tests. A series of immunology assays will be performed to determine how potent the vaccine is at inducing an immune response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The volunteer must satisfy all the following criteria to be eligible for the study:
- •Men and women aged 18-50
- •Resident in or near Oxford for the duration of the vaccination study
- •Able and willing (in the Investigators' opinions) to comply with all study requirements
- •Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner
- •Willingness to use effective contraception for 4 weeks from the date of vaccination
- •Agreement to refrain from blood donation for 4 weeks from the date of vaccination
- •Written informed consent
排除标准
- •The volunteer may not enter the study if any of the following apply:
- •Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period
- •Previous receipt of any recombinant adenoviral vectored vaccine
- •Previous receipt of MVA-NP+M1
- •Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
- •Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled/topical steroids are allowed)
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
- •Any history of anaphylaxis in reaction to vaccination
- •History of cancer (except basal cell carcinoma and cervical carcinoma in situ)
- •History of serious psychiatric condition
- •Any chronic illness requiring ongoing or awaiting hospital specialist supervision, other than minor surgical procedures and follow up of surgery over 6 months prior to screening.
- •Suspected or known current injecting drug or alcohol abuse (as defined by an alcohol intake of greater than 42 units every week)
- •Seropositive for hepatitis B surface (HBsAg) or hepatitis C virus (antibodies to HCV)
- •Pregnancy, lactation or willingness/intention to become pregnant during the study
- •Any other significant disease, disorder or finding (including blood test results), which, in the opinion of the Investigators, would either put the volunteer at risk because of participation in the study, or may influence the result of the study.
- •No response / confirmation from GP regarding previous medical history
结局指标
主要结局
Safety
时间窗: 3 weeks
Analysis of data on adverse events.
次要结局
- Reactogenicity(3 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy AdultsMalariaNCT02013687Fraunhofer, Center for Molecular Biotechnology44
已完成
1 期
Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)Covid19SARS CoV 2 InfectionNCT05007509Laboratorios Hipra, S.A.30
终止
1 期
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UKPlasmodium FalciparumMalariaNCT05400746University of Oxford17
已完成
1 期
A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple MyelomaMultiple MyelomaNCT01025206BioInvent International AB35
已完成
1 期
A Phase I Study of MSB2311 in Advanced Solid TumorsAdvanced Solid TumorsNCT03463473Suzhou Transcenta Therapeutics Co., Ltd.42